Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 15, 2005. The report details changes in the interests of directors, persons discharging managerial responsibility, or connected persons regarding the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share transactions rather than a financial performance report.
Material Changes
The filing reports specific transactions involving the GlaxoSmithKline (US) Trust ("GSK US Trust") on December 12, 2005:
- Abacus Corporate Trustee Limited sold 1,972 ADR Shares to participants in the GlaxoSmithKline Restricted Share Plan at $50.99 per share.
- Abacus Corporate Trustee Limited transferred 4,093 ADR Shares to participants in the same plan.
These transactions were advised to the company on December 15, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses a transaction notified under Disclosure Rule 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Price: ADR shares were sold to plan participants at $50.99.
- Trust Structure: The GSK US Trust is a grantor trust for employees or former employees of SmithKline Beecham Corporation and its subsidiaries.
- Director Interests: Directors Dr. J-P Garnier and Dr. T Yamada hold interests in the shares held by the GSK US Trust in the same capacity as other eligible employees.
- Volume: A total of 6,065 ADR shares were involved in the sale and transfer activities reported.